Scarica l'app Stockscreener
289.25
0.42%
1.20
Dopo l'orario di chiusura:
289.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$288.05
Aprire:
$285
Volume 24 ore:
146.55K
Relative Volume:
0.42
Capitalizzazione di mercato:
$5.77B
Reddito:
$274.48M
Utile/perdita netta:
$153.56M
Rapporto P/E:
39.22
EPS:
7.3755
Flusso di cassa netto:
$114.06M
1 W Prestazione:
-0.17%
1M Prestazione:
-2.18%
6M Prestazione:
+36.25%
1 anno Prestazione:
+74.28%
Intervallo 1D:
$283.04
$291.26
Intervallo di 1 settimana:
$278.40
$291.82
Portata 52W:
$161.82
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
289.25 | 5.74B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand executives will meet investors at three September events - Stock Titan
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand (LGND) Chart: Retreats 0.38% to $286.29 in Latest Trading; Chart Watch: $271.98 and $300.60 Define the Nearby Reference Levels in the Available RecordMomentum Trade - vinanet.vn
$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga
LGND6487833 Bond Profile — Key Metrics - TradingView
LGND6487833 Bond Yield and Price — FINRA:LGND6487833 - TradingView
Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand (LGND) Q2 2026 Earnings Call Transcript - AOL.com
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock - Moomoo
Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com South Africa
Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK
Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan
LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat
Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance
Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance
Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan
Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan
Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - Moomoo
Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
LGND: XOMA Acquisition Closed - Smartkarma
Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):